Accelerated cancer drug approvals yield modest survival gains at significant Medicare cost

Early access to new cancer drugs, granted accelerated approval by the U.S. Food and Drug Administration (FDA), has provided mixed benefits for patients while costing Medicare billions of dollars, reveals research published in the journal BMJ…

Continue Reading

News Source: medicalxpress.com